A new $16,000 postpartum depression drug is here. How will insurers handle it?
By April Dembosky, KQED and KFF Health News A much-awaited treatment for postpartum depression, zuranolone, hit the market in December, promising an accessible and fast-acting medication for a debilitating illness. But most private health insurers have yet to publish criteria … Continued